News

Press & Publications

United Neuroscience and Boston University Lee Goldstein Laboratory Form Collaboration to Research Tau-Targeted Therapeutics for Treatment and Prevention of Chronic Traumatic Encephalopathy (CTE)

News Release  |  April 16, 2018

UNS announced that it has signed a collaboration agreement with the Lee Goldstein laboratory at the Boston University School of Medicine to investigate the potential of Endobody vaccines developed by United Neuroscience to target pathogenic forms of tau protein


United Neuroscience and University of Texas Southwestern Medical Center Announce Collaboration to Evaluate Endobody Vaccine Candidates Directed at Tau Protein for the Treatment and Prevention of Alzheimer’s Disease

News Release  |  April 11, 2018

UNS announced that it has signed a collaboration agreement with the Center for Alzheimer's and Neurodegenerative Diseases at the UTSW Medical Center to identify distinct pathogenic species of tau protein and evaluate promising therapeutic vaccine candidates to contribute to therapies for Alzheimer's and other neurodegenerative diseases


United Neuroscience Signs Collaboration Agreement with French National Center for Scientific Research (CNRS) Laboratory to Target Protein Associated with Parkinson’s Disease

News Release  |  March 22, 2018

United Neuroscience announced that it has entered a research collaboration agreement with the Ronald Melki laboratory at the French National Center for Scientific Research (CNRS) to investigate applications of the United Neuroscience Endobody technology platform in targeting pathogenic forms of alpha-synuclein protein


United Neuroscience to Present at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics

News Release  |  February 28, 2018

United Neuroscience announces that the company will present at the upcoming 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT) conference being held March 7-10, 2018


Could A Vaccine Protect Football Players From Concussions?

WIRED  |  February 2, 2018

United Neuroscience developing a drug designed to inoculate the brain against CTE


United Neuroscience Announces Development Plans for Vaccine to Prevent CTE

News Release  |  January 29, 2018

UNS announced plans for the development of a vaccine for the prevention of chronic traumatic encephalopathy (CTE)


United Neuroscience Featured On ABC News Radio

ABC News Radio  |  January 10, 2018

National Radio News Network Covers United Neuroscience Alzheimer’s Vaccine Program


Life-Saving Innovations On Display At JPMorgan Healthcare Conference

ABC 7 News  |  January 8, 2018

United Neuroscience Alzheimer’s Vaccine Program featured along with the Bill and Melinda Gates Foundation at JPMorgan Healthcare Conference 2018


Global Health: Partnerships Hold The Key

Pharmaceutical Executive  |  December 29, 2017

Amid a widening net of global health threats, alliances in research and response may be more crucial than ever


Brain Hacking: What Bill Gates And Other Tech Titans Want With Our Mind

NBC News  |  December 29, 2017

United Neuroscience Co-Founder, Lou Reese quoted in NBC News Segment looking at new technological approaches to tackling Alzheimer’s and other neurodegenerative diseases


United Neuroscience’s Mei Mei Hu Interviewed by MSNBC’s Ali Velshi

MSNBC  |  December 27, 2017

Alzheimer's disease treatments and United Neuroscience's plans for a vaccine on MSNBC.


Ace Of BACE? Mechanism May Block AD Before Symptoms

BioWorld  |  November 6, 2017

Bioworld article heralding United Neuorscience’s endobody prospect in tackling Alzheimer’s Disease


As Alz Players Stand United, New A-Beta Bids Also To Fall?

BioWorld  |  November 3, 2017

Bioworld article recognizing the strides United Neuorscience’s endobody work has made in tackling Alzheimer’s Disease


United Neuroscience Presents Data For Phase 2 Active Vaccine Program UB-311 At The Clinical Trials On Alzheimer’s Disease 2017 Meeting

News Release  |  November 1, 2017

United Neuroscience, a clinical stage biotechnology company dedicated to developing best-in-class therapies for Alzheimer's disease, neurodegenerative disorders and orphan indications in neurology, today announced analyses of data for UB-311, its novel synthetic peptide vaccine targeting beta amyloid (Aβ) in the treatment of AD


UB-311, A Novel UBITh® Amyloid β Peptide Vaccine For Mild Alzheimer’s Disease

Alzheimer's & Dementia: Translational Research & Clinical Interventions  |  June 15, 2017

The UBITh® platform can generate a high-precision molecular vaccine with high responder rate, strong on-target immunogenicity, and a potential of cognition improvement, which support UB-311 for active immunotherapy in early-to-mild AD patients currently enrolled in a phase-II trial


United Neuroscience Names Ajay Verma Chief Medical Officer

Alzheimer's & Dementia: Translational Research & Clinical Interventions  |  March 20, 2017

Xconomy article announcing the hire of Ajay Verma, formerly head of Neuroscience at Biogen, into the position of Chief Medical Officer